About the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. Session
Hematologic malignancies represent cancers of the blood and lymphatic systems. Leukemia research has seen breakthroughs in CAR-T cell therapies and precision medicine, revolutionizing treatment outcomes. Lymphomas, including Hodgkin and non-Hodgkin types, benefit from immunotherapy and monoclonal antibodies targeting specific pathways. Multiple myeloma, a plasma cell cancer, has shown improved prognosis with proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation. Research focuses on unraveling molecular mechanisms, resistance patterns, and novel drug development to manage these diseases effectively. Clinical trials and advancements in diagnostics continue to push boundaries, offering hope for better management and potential cures.
Topics Covered in Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma.
Leukemia Genomics
Aggressive Lymphomas
Plasma Cell Disorders
Proteasome Inhibitors
CAR-T Cell Therapy
Stem Cell Transplantation
Related Scientific Sessions at CIOC 2027
Why Attend the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. Conference 2027 — FAQs
What is the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. track at CIOC 2027?
The Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma.. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. sessions?
Cancer researchers and clinicians, educators and students with an interest in Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. are all welcome — whether presenting or attending.
Can I present my research in the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Hematologic Malignancies: Leukemia, Lymphoma, Multiple Myeloma. track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.